Thanks for the great commentary everyone.
I think Neuren’s best chance at Breakthrough Therapy Designation will be for TBI:
-the phase 2 trial has clear clinically significant endpoints, being reduced incidence of adverse events and serious adverse events; and
-the trial size (260 subjects) lends itself to the statistical power the FDA generally likes to see.
If the phase ii trial in TBI is successful, I think we will have a reasonable chance of obtaining BTD. However I can’t see us getting BTD for Fragile X at this stage, given the phase 2 trial design was very similar to Rett…although I would love to be proved wrong.
- Forums
- ASX - By Stock
- NEU
- License or Buyout?
License or Buyout?, page-27
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$15.34 |
Change
-0.410(2.60%) |
Mkt cap ! $1.960B |
Open | High | Low | Value | Volume |
$15.88 | $15.93 | $15.34 | $6.463M | 415.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 6044 | $15.32 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.57 | 1411 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 170 | 15.600 |
1 | 36 | 15.410 |
3 | 2085 | 15.400 |
4 | 1583 | 15.300 |
2 | 1448 | 15.290 |
Price($) | Vol. | No. |
---|---|---|
14.580 | 346 | 1 |
15.300 | 500 | 1 |
15.400 | 3 | 1 |
15.500 | 303 | 1 |
15.750 | 630 | 1 |
Last trade - 16.10pm 28/08/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
UNT
UNITH LTD
Idan Schmorak, CEO
Idan Schmorak
CEO
Previous Video
Next Video
SPONSORED BY The Market Online